Flexion Therapeutics (NASDAQ:FLXN)‘s stock had its “outperform” rating reissued by research analysts at BMO Capital Markets in a research note issued to investors on Friday, March 9th. They presently have a $36.00 price target on the specialty pharmaceutical company’s stock, down from their prior price target of $37.00. BMO Capital Markets’ target price would indicate a potential upside of 65.14% from the company’s current price.
FLXN has been the topic of a number of other research reports. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 5th. BidaskClub cut Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 30th. Northland Securities reaffirmed a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research report on Friday, November 10th. Finally, Berenberg Bank started coverage on Flexion Therapeutics in a research report on Thursday, February 1st. They set a “buy” rating and a $42.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $99.00.
NASDAQ:FLXN traded down $0.61 during mid-day trading on Friday, reaching $21.80. 666,070 shares of the stock were exchanged, compared to its average volume of 758,832. The company has a market capitalization of $843.05, a PE ratio of -5.24 and a beta of 0.84. The company has a quick ratio of 12.96, a current ratio of 13.02 and a debt-to-equity ratio of 0.58. Flexion Therapeutics has a 1 year low of $16.51 and a 1 year high of $32.25.
Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings results on Thursday, March 8th. The specialty pharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.27). The company had revenue of $0.36 million during the quarter, compared to analysts’ expectations of $1.29 million. sell-side analysts anticipate that Flexion Therapeutics will post -4.89 EPS for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN lifted its holdings in shares of Flexion Therapeutics by 1,024.1% in the 4th quarter. Wells Fargo & Company MN now owns 1,706,942 shares of the specialty pharmaceutical company’s stock valued at $42,742,000 after buying an additional 1,555,093 shares during the period. State Street Corp lifted its holdings in shares of Flexion Therapeutics by 66.3% in the 2nd quarter. State Street Corp now owns 1,379,202 shares of the specialty pharmaceutical company’s stock valued at $27,888,000 after buying an additional 549,948 shares during the period. BlackRock Inc. lifted its holdings in shares of Flexion Therapeutics by 17.4% in the 4th quarter. BlackRock Inc. now owns 2,650,986 shares of the specialty pharmaceutical company’s stock valued at $66,381,000 after buying an additional 392,055 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Flexion Therapeutics in the 4th quarter valued at approximately $7,712,000. Finally, Ardsley Advisory Partners lifted its holdings in shares of Flexion Therapeutics by 137.1% in the 4th quarter. Ardsley Advisory Partners now owns 415,000 shares of the specialty pharmaceutical company’s stock valued at $10,392,000 after buying an additional 240,000 shares during the period. 94.46% of the stock is owned by institutional investors.
WARNING: This article was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://theenterpriseleader.com/2018/04/02/bmo-capital-markets-reaffirms-outperform-rating-for-flexion-therapeutics-nasdaqflxn.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.